

Francesca Romana Mauro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8342411/publications.pdf>

Version: 2024-02-01

176
papers

5,395
citations

109137

35
h-index

95083

68
g-index

176
all docs

176
docs citations

176
times ranked

5615
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas. <i>Hematological Oncology</i> , 2023, 41, 571-573.	0.8	0
2	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. <i>Haematologica</i> , 2022, 107, 868-876.	1.7	31
3	Treatment with ibrutinib does not induce a $TP53$ clonal evolution in chronic lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 334-337.	1.7	4
4	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
5	Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. <i>Haematologica</i> , 2022, 107, 1470-1473.	1.7	12
6	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 332-340.	0.8	3
7	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	3
8	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 518-527.	0.8	4
9	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-immunotherapy. <i>British Journal of Haematology</i> , 2022, 198, 103-113.	1.2	7
10	Continuous treatment with Ibrutinib in 100 untreated patients with $TP53$ disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	14
11	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
12	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	3.3	17
13	Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study. <i>Haematologica</i> , 2021, 106, 622-625.	1.7	39
14	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia</i> , 2021, 35, 737-746.	3.3	61
15	Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients. <i>Hematological Oncology</i> , 2021, 39, 141-144.	0.8	3
16	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	1.1	5
17	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	2.0	10
18	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8

#	ARTICLE	IF	CITATIONS
19	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637186.	1.3	17
20	<i>TP53</i> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	2.0	8
21	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab+bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	2.0	3
22	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	0.6	30
23	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	1.7	16
24	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	0.8	9
25	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621.	1.3	6
26	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. <i>Blood</i> , 2021, 138, 2727-2730.	0.6	9
27	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. <i>Blood Advances</i> , 2021, , .	2.5	14
28	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
29	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. <i>Haematologica</i> , 2021, 106, 1500-1503.	1.7	7
30	Increased eryptosis in patients with primary antiphospholipid syndrome (APS): a new actor in the pathogenesis of APS. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 838-843.	0.4	1
31	HIF-1 α is over-expressed in leukemic cells from <i>TP53</i> -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	1.7	39
32	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	1.3	12
33	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	2.8	7
34	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
35	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	0.6	33
36	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. <i>Frontiers in Oncology</i> , 2020, 10, 848.	1.3	5

#	ARTICLE	IF	CITATIONS
37	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
38	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. <i>Cancers</i> , 2020, 12, 1773.	1.7	4
39	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. <i>American Journal of Hematology</i> , 2020, 95, 604-611.	2.0	12
40	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <i>Haematologica</i> , 2020, 105, 2671-2674.	1.7	1
41	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	0.6	33
42	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	1.7	64
43	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , 2020, 189, 853-859.	1.2	18
44	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	0.6	1
45	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	0.6	0
46	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
47	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. <i>Blood</i> , 2020, 136, 33-34.	0.6	1
48	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
49	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. <i>Blood</i> , 2020, 136, 54-55.	0.6	2
50	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. <i>Blood</i> , 2020, 136, 25-26.	0.6	3
51	Biallelic <i>BIRC3</i> inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. <i>British Journal of Haematology</i> , 2019, 185, 156-159.	1.2	9
52	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	0.8	13
53	Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	1.2	14
54	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. <i>Leukemia Research</i> , 2019, 87, 106233.	0.4	16
56	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2019, 121, 150-156.	2.9	31
57	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 2053-2060.	1.7	60
58	Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib. <i>British Journal of Haematology</i> , 2019, 184, 392-396.	1.2	9
59	Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia. <i>Blood</i> , 2019, 134, 3516-3516.	0.6	2
60	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
61	Gene mutations in lenalidomide-treated CLL. <i>Blood</i> , 2018, 131, 1769-1771.	0.6	2
62	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
63	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873.	3.3	8
64	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , 2018, 181, 229-233.	1.2	34
65	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 681-697.	4.2	65
66	Comparison between the CLL-IPI and the B ₂ 20 prognostic model: Analysis of 1299 newly diagnosed cases. <i>American Journal of Hematology</i> , 2018, 93, E35-E37.	2.0	18
67	Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib. <i>Lancet Oncology</i> , The, 2018, 19, 7-8.	5.1	1
68	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 601-611.	1.0	10
69	Predictive value of the CLL-IPI in CLL patients receiving chemoimmunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018, 101, 703-706.	1.1	8
70	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219.	2.0	15
71	Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. <i>Blood</i> , 2018, 132, 4954-4954.	0.6	3
72	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412.	0.6	2
74	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. <i>Blood</i> , 2018, 132, 1834-1834.	0.6	1
75	Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region. <i>Blood</i> , 2018, 132, 5550-5550.	0.6	0
76	The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 1844-1844.	0.6	0
77	TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. <i>Blood</i> , 2018, 132, 3119-3119.	0.6	1
78	Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. <i>Lancet Oncology</i> , The, 2017, 18, 270-271.	5.1	1
79	Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 529-535.	2.0	20
80	Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2017, 57, 65-71.	0.4	17
81	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	1.7	9
82	Clinical relevance of silent red blood cell autoantibodies. <i>Haematologica</i> , 2017, 102, e473-e475.	1.7	9
83	Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib. <i>Chemotherapy</i> , 2017, 62, 350-352.	0.8	1
84	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase II GIMEMA trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 1640-1647.	0.6	8
85	Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic workup. <i>American Journal of Hematology</i> , 2016, 91, E319-20.	2.0	0
86	Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. <i>British Journal of Haematology</i> , 2016, 172, 371-383.	1.2	20
87	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. <i>Blood</i> , 2016, 128, 2093-2095.	0.6	52
88	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016, 60, 154-165.	1.3	22
89	A case of concomitant chronic lymphocytic leukaemia and hairy cell leukaemia evaluated for IGHV rearrangements and BRAF V600E mutation: lack of evidence for a common origin. <i>British Journal of Haematology</i> , 2016, 174, 329-331.	1.2	4
90	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€œCLLâ€œGISL study. <i>European Journal of Haematology</i> , 2016, 96, 36-45.	1.1	7

#	ARTICLE	IF	CITATIONS
91	Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Review of Hematology, 2016, 9, 1165-1175.	1.0	6
92	Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. Leukemia and Lymphoma, 2016, 57, 2429-2431.	0.6	10
93	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. Blood, 2016, 128, 2038-2038.	0.6	3
94	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. Blood, 2016, 128, 3240-3240.	0.6	0
95	HIF-1 α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. Blood, 2016, 128, 305-305.	0.6	0
96	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood, 2015, 126, 1921-1924.	0.6	197
97	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-12. Genes Chromosomes and Cancer, 2015, 54, 222-234.	1.5	26
98	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. Leukemia Research, 2015, 39, 1066-1070.	0.4	29
99	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. Blood, 2015, 126, 2946-2946.	0.6	1
100	Is Idelalisib Cost-Effective for Refractory/Relapsed Chronic Lymphocytic Leukemia? a Decision Analysis in the Second-Line Setting. Blood, 2015, 126, 3305-3305.	0.6	3
101	A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. Blood, 2015, 126, 2930-2930.	0.6	0
102	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B α cell receptor structure, function, and patients' prognosis. American Journal of Hematology, 2014, 89, 74-82.	2.0	20
103	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology, 2014, 89, 480-486.	2.0	104
104	Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. British Journal of Haematology, 2014, 167, 224-232.	1.2	25
105	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leukemia Research, 2014, 38, 1269-1277.	0.4	13
106	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood, 2014, 123, 2378-2388.	0.6	78
107	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. Leukemia Research, 2014, 38, 198-203.	0.4	4
108	Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ \pm PCR. British Journal of Haematology, 2014, 166, 360-368.	1.2	27

#	ARTICLE	IF	CITATIONS
109	<i>NOTCH1, SF3B1, BIRC3</i> and <i>TP53</i> mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 2785-2792.	0.6	47
110	BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion. <i>Blood</i> , 2014, 124, 3295-3295.	0.6	3
111	Total body computed tomography scan in the initial workup of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter Oâ€œCLL1â€œGSL study. <i>American Journal of Hematology</i> , 2013, 88, 539-544.	2.0	10
112	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412.	0.6	420
113	Chromosome 2p gain in monoclonal Bâ€œcell lymphocytosis and in early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 24-31.	2.0	27
114	Bâ€œcell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013, 88, 32-36.	2.0	36
115	IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells. <i>Leukemia Research</i> , 2013, 37, 455-462.	0.4	7
116	Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. <i>Haematologica</i> , 2013, 98, 371-375.	1.7	15
117	ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. <i>Haematologica</i> , 2012, 97, 47-55.	1.7	92
118	Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications. <i>Leukemia and Lymphoma</i> , 2012, 53, 1660-1665.	0.6	10
119	Behind the scenes of nonâ€œnodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, <i>TP53</i> pathway and mutated status of immunoglobulin heavy chain genes. <i>British Journal of Haematology</i> , 2012, 156, 601-611.	1.2	21
120	An Italian retrospective study on the routine clinical use of lowâ€œdose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 481-489.	1.2	17
121	A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. <i>Experimental Hematology</i> , 2012, 40, 197-206.e1.	0.2	15
122	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 459-466.	0.4	7
123	NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment. <i>Blood</i> , 2012, 120, 1784-1784.	0.6	2
124	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1780-1780.	0.6	0
125	Longitudinal analysis of human herpesvirus-8 DNA and antibodies in an Italian allogeneic stem cell transplant recipient. <i>Journal of Clinical Virology</i> , 2011, 52, 247-250.	1.6	5
126	Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. <i>Haematologica</i> , 2011, 96, 277-283.	1.7	47

#	ARTICLE	IF	CITATIONS
127	Enteral nutrition may cause false-positive results of Aspergillus Galactomannan assay in absence of gastrointestinal diseases. <i>Mycoses</i> , 2011, 54, e883-e884.	1.8	16
128	5-azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. <i>Leukemia Research</i> , 2011, 35, 1409-1411.	0.4	3
129	Chronic lymphocytic leukemia in less fit patients: a slow-growth. <i>Leukemia and Lymphoma</i> , 2011, 52, 2207-2216.	0.6	18
130	The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: A retrospective multicentric GIMEMA experience. <i>American Journal of Hematology</i> , 2011, 86, 1007-1012.	2.0	47
131	Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 263-274.	1.5	25
132	White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. <i>Haematologica</i> , 2011, 96, 626-630.	1.7	27
133	Is the Aberrant Expression of p53 by Immunocytochemistry a Surrogate Marker of TP53 Mutation and/or Deletion in Chronic Lymphocytic Leukemia?. <i>American Journal of Clinical Pathology</i> , 2011, 135, 173-174.	0.4	4
134	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011, 118, 294-294.	0.6	6
135	Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors. <i>Leukemia Research</i> , 2010, 34, 733-741.	0.4	12
136	The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. <i>Haematologica</i> , 2010, 95, 464-469.	1.7	37
137	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. <i>Blood</i> , 2010, 116, 2462-2462.	0.6	17
138	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. <i>Blood</i> , 2010, 116, 2471-2471.	0.6	2
139	Fludarabine, Cyclophosphamide and Lenalidomide (FCL) for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL): Results of the Dose-Finding Phase of the GIMEMA LLC606 Study. <i>Blood</i> , 2010, 116, 1377-1377.	0.6	1
140	Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial. <i>Blood</i> , 2010, 116, 1360-1360.	0.6	2
141	Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly. <i>British Journal of Haematology</i> , 2009, 144, 726-731.	1.2	51
142	Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. <i>Blood</i> , 2009, 114, 638-646.	0.6	65
143	Identification of monoclonal B-cell lymphocytosis among sibling transplant donors for chronic lymphocytic leukemia patients. <i>Blood</i> , 2009, 114, 2848-2849.	0.6	20
144	Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2008, 142, 202-215.	1.2	206

#	ARTICLE	IF	CITATIONS
145	BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. <i>Blood</i> , 2008, 112, 782-792.	0.6	121
146	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. <i>Blood</i> , 2008, 111, 5691-5693.	0.6	30
147	A Prospective Study of Young Chronic Lymphocytic Leukemia (CLL) Patients Investigated at Diagnosis: Distribution and Clinical Significance of Prognostic Factors. <i>Blood</i> , 2008, 112, 3121-3121.	0.6	0
148	ATM Gene Alterations in CLL Patients Induce Gene Profile Clusters and Predict Disease Progression.. <i>Blood</i> , 2008, 112, 2084-2084.	0.6	0
149	A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. <i>Blood</i> , 2007, 110, 3326-3333.	0.6	79
150	Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. <i>Blood</i> , 2007, 109, 4944-4951.	0.6	471
151	IgVH Germline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.. <i>Blood</i> , 2007, 110, 1133-1133.	0.6	1
152	The MicroRNA (miR) Profile in B-Cell Chronic Lymphocytic Leukemia (CLL) Reveals a Differential Expression of miR-21, miR-155 and miR-150 between Leukemic and Normal B Lymphocytes, and of miR-150, miR-29bc and miR-223 between IgVH Mutated and Unmutated Patients.. <i>Blood</i> , 2006, 108, 298-298.	0.6	1
153	Gene Expression Profile of Protein Kinases Reveals a Distinctive Signature of Chronic Lymphocytic Leukemia (CLL) and Points to a Role of Second Generation Protein Kinase Inhibitors.. <i>Blood</i> , 2006, 108, 2794-2794.	0.6	0
154	Histopathologic and Molecular Features of Persistent Polyclonal B-Cell Lymphocytosis Challenging the Benign Nature of the Disorder.. <i>Blood</i> , 2006, 108, 4612-4612.	0.6	0
155	Chronic Lymphocytic Leukemia (CLL) with Discordance in ZAP-70 Expression and IgVH Mutation Status.. <i>Blood</i> , 2006, 108, 2787-2787.	0.6	0
156	Angiogenic Activity in IgVH Mutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.. <i>Blood</i> , 2006, 108, 2819-2819.	0.6	0
157	Clinical features and outcome of familial chronic lymphocytic leukemia. <i>Haematologica</i> , 2006, 91, 1117-20.	1.7	35
158	Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2006, 91, 1689-92.	1.7	61
159	Bullous lesions in chronic lymphocytic leukaemia: pemphigoid or insect bites?. <i>Acta Dermato-Venereologica</i> , 2006, 86, 74-76.	0.6	13
160	New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. <i>Current Opinion in Oncology</i> , 2005, 17, 597-604.	1.1	21
161	The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. <i>British Journal of Haematology</i> , 2005, 130, 549-557.	1.2	51
162	Familial Cancer Associated with a Polymorphism in ARLTS1. <i>New England Journal of Medicine</i> , 2005, 352, 1667-1676.	13.9	119

#	ARTICLE	IF	CITATIONS
163	A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 553-560.	0.6	21
164	A High-Density SNP Genomewide Linkage Scan for Chronic Lymphocytic Leukemiaâ€“Susceptibility Loci. <i>American Journal of Human Genetics</i> , 2005, 77, 420-429.	2.6	65
165	Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19+ cells in vivo and in vitro. <i>British Journal of Haematology</i> , 2004, 125, 720-728.	1.2	27
166	Immunoglobulin (Ig) Variable Gene Usage Identifies a Subset of Unmutated Chronic Lymphocytic Leukemia (CLL) Patients Expressing 51p1-Like alleles and a Particularly Unfavorable Prognostic Outcome.. <i>Blood</i> , 2004, 104, 1922-1922.	0.6	0
167	Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. <i>Blood</i> , 2003, 102, 1035-1041.	0.6	74
168	Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 113, 391-399.	1.2	26
169	Hodgkin / Reed-Sternberg cells and Hodgkin's disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 129-132.	1.4	42
170	Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. <i>Blood</i> , 2000, 95, 2786-2792.	0.6	261
171	Clinical Characteristics and Outcome of Young Chronic Lymphocytic Leukemia Patients: A Single Institution Study of 204 Cases. <i>Blood</i> , 1999, 94, 448-454.	0.6	203
172	VH gene usage by family members affected with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1999, 107, 616-624.	1.2	45
173	p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. <i>Blood</i> , 1998, 91, 4342-4349.	0.6	176
174	Late listeriosis after fludarabine plus prednisone treatment. <i>British Journal of Haematology</i> , 1994, 87, 407-408.	1.2	14
175	Monocytopenia and infections in chronic lymphocytic leukemia (CLL). <i>European Journal of Haematology</i> , 1991, 46, 119-119.	1.1	12
176	Standard conditioning regimen and t-depleted donor bone marrow for transplantation in chronic myeloid leukemia. <i>Leukemia Research</i> , 1986, 10, 1469-1475.	0.4	14